Rekambys (rilpivirine LA) / J&J - LARVOL DELTA

Long-acting Injectable Antiretroviral Therapy in South African Adolescents and Young Adults - Week 48 results from the AFINAty Study. (PubMed, J Acquir Immune Defic Syndr) - "LAI-ART was safe, highly acceptable and effective among YLHIV. These findings support the feasibility of implementing LAI-ART through community-based models in sub-Saharan Africa."

Journal • Human Immunodeficiency Virus • Infectious Disease

Modelling the tail-phase pharmacokinetics of long-acting cabotegravir and rilpivirine from early pregnancy to postpartum at steady state. (PubMed, J Pharmacokinet Pharmacodyn) - "Long-acting cabotegravir and rilpivirine combination (LA-CAB/RPV) is approved for HIV treatment whilst LA-CAB alone is approved for HIV prevention, both in adults. Pharmacokinetic tails of LA-CAB/RPV extend to several months postpartum, with levels falling below established minimum effective concentration in most women after gestation week 33. Potential strategies to minimise potential risks associated with LA-CAB/RPV discontinuation in this population are needed."

Journal • PK/PD data • Human Immunodeficiency Virus • Infectious Disease

Switch to injectable cabotegravir-rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial. (PubMed, Lancet) - P3 | "In adolescents with HIV with virological suppression, LAI cabotegravir-rilpivirine was superior to TLD for maintaining virological suppression, with no new safety concerns observed. These findings support LAI cabotegravir-rilpivirine as a maintenance treatment option for this population."

Head-to-Head • Journal • Human Immunodeficiency Virus • Immunology • Infectious Disease • Oncology • Osteosarcoma • Pulmonary Disease • Respiratory Diseases • Sarcoma • Solid Tumor • Tuberculosis

The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE (clinicaltrials.gov) - P3 | N=456 | Completed | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting ➔ Completed

Trial completion • Human Immunodeficiency Virus • Infectious Disease

Use of archived proviral HIV-1 DNA genotype to review eligibility prior to initiation with CAB/RPV long-acting antiretroviral therapy (IDWeek 2026) - No abstract available

Review • Human Immunodeficiency Virus • Infectious Disease

Narrative Review of Two-Drug Regimens in Modern HIV Care: Driving Innovation, Flexibility, and Quality of Life. (PubMed, Infect Dis Ther) - "Dolutegravir/lamivudine, dolutegravir/rilpivirine and long-acting cabotegravir/rilpivirine are the regimens studied the most, supported by randomised trials and real-world evidence. Long-acting injectable strategies may be particularly valuable for individuals who face challenges with daily oral adherence or treatment-related stigma. This narrative review summarizes current evidence on the role of oral and injectable 2DRs in key domains including innovation, flexibility, tolerability, adherence and quality of life, while discussing current limitations and future perspectives."

HEOR • Journal • Review • Human Immunodeficiency Virus • Infectious Disease

Impact of implementation process on long-acting cabotegravir/rilpivirine prescription at 9 HIV clinics, 2021-2024. (PubMed, J Acquir Immune Defic Syndr) - "Barriers related to insurance coverage and drug procurement impacted the number of PWH prescribed LA-CAB/RPV as did processes to plan for, and adapt to, these barriers. Scale-up efforts should consider team coordination and EHR-facilitated tracking to support the growing number of PWH on LA-CAB/RPV."

Journal • Human Immunodeficiency Virus • Infectious Disease

Long-acting cabotegravir and rilpivirine in people with HIV receiving chronic anticoagulation: A real-world case series. (PubMed, Br J Clin Pharmacol) - "This real-world case series suggest that chronic anticoagulant therapy alone should not automatically preclude the use of LA-CAB + RPV. With careful patient selection and appropriate injection techniques, LA-CAB + RPV may represent a safe and effective treatment option for selected people with HIV receiving anticoagulation."

Journal • Real-world evidence • Human Immunodeficiency Virus • Infectious Disease

Long-Acting Injectable Cabotegravir/Rilpivirine as a Second-Line ART Regimen for Pregnant and Breastfeeding Women in Kenya: Modeling the Potential Impact on Vertical Transmission. (PubMed, Open Forum Infect Dis) - "Switching to injectable long-acting cabotegravir and rilpivirine (LA-CAB/RPV) may improve viral suppression among pregnant and breastfeeding women (PBFW) who have persistent viremia on first-line antiretroviral therapy (ART), resulting in the prevention of vertical transmission (PVT). We used a microsimulation model of PBFW living with HIV in Kenya on dolutegravir-based first-line ART to evaluate the PVT potential of LA-CAB/RPV in 2 maternal populations-newly positive (NP) pregnant women who initiate ART during antenatal care, and known positive (KP) women who initiate ART prior to conception-during antenatal care through 18 months postpartum...These reductions increased to 4.0% and 11.5%, respectively, when assuming perfect adherence to more frequent VL monitoring (3-month intervals) and 100% regimen switching when eligible. Supporting high switching rates and decreasing delays in switching will help optimize the PVT impact of second-line LA-CAB/RPV among PBFW who..."

Journal • Human Immunodeficiency Virus • Infectious Disease

A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed (clinicaltrials.gov) - P3 | N=564 | Recruiting | Sponsor: ViiV Healthcare | Not yet recruiting ➔ Recruiting

Enrollment open • Head-to-Head • Human Immunodeficiency Virus • Infectious Disease

CRAYON: Cabotegravir and Rilpivirine Long-Acting Injections in Young Children (clinicaltrialsregister.eu) - P1/2 | N=90 | Sponsor: National Institute of Allergy and Infectious Diseases, Division of AIDS

New P1/2 trial • Human Immunodeficiency Virus • Infectious Disease

Mitigating intellectual property barriers to HIV and comorbidities treatment in Eurasian Patent Organization countries: programme results and policy implications (AIDS 2026) - "The drugs included tenofovir/emtricitabine (Armenia, Russia), rilpivirine (Russia), long-acting rilpivirine, islatravir, lenacapavir (EAPO); sofosbuvir (Russia); molnupiravir (EAPO, Russia), nirmatrelvir (EAPO); pretomanid in bedaquiline/pretomanid/linezolid regimen, pretomanid granulate, pretomanid amorphous form (EAPO), bedaquiline (Belarus, Kazakhstan, Kyrgyzstan). EECA communities developed expertise on patent challenges, successfully opposed patents, and revealed and addressed systemic barriers to CSO engagement in access-related IP work. The programme has potential for expansion, as demonstrated by a CBO opposition in Uzbekistan in December 2025 (delamanid). Results from the structural barrier analysis call for legal reform to enhance community involvement in mitigating IP barriers and improving access to medicines."

Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • Tuberculosis

Incidence of mutational patterns affecting doravirine or/and rilpivirine in people living with HIV and previous failure with NNRTIs efavirenz or nevirapine (AIDS 2026) - "BACKGROUND: The growing use of new non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as doravirine (DOR) or long-acting rilpivirine (RPV) makes necessary to evaluate the impact of previous failure to NNRTIs. Our results confirm that doravirine resistance in NNRTI-failing PLWH is lower than resistance to other NNRTIs currently used. However, these data suggest considering carefully genotypic resistance test results before the use of RPV or DOR in the clinical setting in those PLWH with previous failure to NNRTIs."

Human Immunodeficiency Virus • Infectious Disease • CD4

CROWN: A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1 (clinicaltrials.gov) - P3 | N=326 | Active, not recruiting | Sponsor: ViiV Healthcare | Recruiting ➔ Active, not recruiting

Enrollment closed • Head-to-Head • Human Immunodeficiency Virus • Infectious Disease

Access to quality affordable WHO-recommended non-TLD first-line HIV treatment – TAF-based, dual oral, and long-acting – regimens in LMICs: mapping the landscape of MPP-licensed products (AIDS 2026) - " Generic TAF-based products (TAF/FTC/DTG 25/200/50 mg and TAF/3TC/DTG 25/300/50 mg tablets), dual DTG-based regimen DTG/3TC (50/300 mg), and CAB-LA (200 mg/mL) + RPV-LA (300 mg/mL) are all potentially accessible in a large number of LMICs (Figure 1-A,B,C). This data shows that, despite limited progress to date, TAF-based and dual oral regimens could be implemented in many more LMICs – covering most of Africa and many countries in Asia, Eastern Europe, Latin America, and the Caribbean – at generic-induced affordable prices, which should further reduce as demand increases. Once developed, CAB-LA+RPV-LA could also be widely accessible."

Clinical • Human Immunodeficiency Virus • Infectious Disease

How place, trust, and care location influence rural and non-metropolitan patients' preferences for decentralized long-acting injectable HIV therapy: A mixed-methods study. (PubMed, BMC Health Serv Res) - "High interest in CAB + RPV LA among non-metropolitan PWH underscores the need for flexible, decentralized delivery models that reduce logistical barriers while maintaining trusted provider relationships."

Journal • Fatigue • Human Immunodeficiency Virus • Infectious Disease

Ultrasound for the determination of appropriate needle length for intragluteal injection of long-acting rilpivirine-cabotegravir. (PubMed, HIV Med) - "Ultrasound is a simple and accessible tool to help optimize drug injection in case of obesity or gynoid fat distribution and investigate injection technique-related issues in cases of VF."

Journal • Genetic Disorders • Human Immunodeficiency Virus • Infectious Disease • Obesity

A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed (clinicaltrials.gov) - P3 | N=564 | Not yet recruiting | Sponsor: ViiV Healthcare

Head-to-Head • New P3 trial • Human Immunodeficiency Virus • Infectious Disease

Effectiveness, Sex Differences, and Patient Experience in Real-World Use of Long-Acting Cabotegravir and Rilpivirine: Results from a Prospective Study. (PubMed, Infect Dis Ther) - "Compared to our general cohort, proportionally fewer women than men switched to LA-CAB/RPV. Effectiveness, adherence, tolerability, and acceptance were high without significant differences by sex. In this study, women expressed more frequent disclosure issues and showed significantly different baseline characteristics compared to men, highlighting the importance of sex-disaggregated data analysis. These results should be confirmed in larger studies."

Journal • Real-world evidence • Human Immunodeficiency Virus • Infectious Disease • CD4

Emerging Trends in HIV-1 Sub-Subtype A6 in Belgium: Transmission Dynamics, Drug Resistance, and Subtyping Tool Evaluation. (PubMed, Viruses) - "The international spread of HIV-1 sub-subtype A6 raises concerns due to its association with contraindications for long-acting injectable formulations of cabotegravir (LA-CAB) and rilpivirine (LA-RPV). HIVdb and ANRS reliably assessed resistance in this therapy-naïve cohort, and HIVdb, COMET, and SmartGene® produced concordant subtyping results. While algorithm choice has little impact at low resistance prevalence, further research is necessary and HIVdb and ANRS remain more suitable for ongoing clinical and research use."

Journal • Human Immunodeficiency Virus • Infectious Disease

VOLITION: A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy (clinicaltrials.gov) - P3 | N=171 | Completed | Sponsor: ViiV Healthcare | Active, not recruiting ➔ Completed

Trial completion • Human Immunodeficiency Virus • Infectious Disease

External Evaluation of Population Pharmacokinetic Models of Cabotegravir, During Its Oral and Intramuscular Administration in HIV-Infected Patients. (PubMed, CPT Pharmacometrics Syst Pharmacol) - "Cabotegravir (CAB), combined with rilpivirine, is the first long-acting injectable therapy approved for HIV-1 maintenance treatment. Therefore, neither model was considered reliable enough for MIPD application in our population. Although Han et al.'s model demonstrated higher predictive performances, further improvements are required before it can be reliably applied for MIPD in daily routine."

Journal • Observational data • PK/PD data • Human Immunodeficiency Virus • Infectious Disease

Safety and efficacy of deltoid intramuscular long-acting cabotegravir and rilpivirine, a case series. (PubMed, Antivir Ther) - "ObjectiveThe objective was to evaluate the safety, pharmacokinetics and efficacy of an alternative deltoid site for CAR-LA.DesignThis is a prospective cohort of people living with HIV (PLWHIV) switching for intramuscular long acting cabotegravir and rilpivirine (CAR-LA).MethodsClinical and biological data were collected at baseline, month 1 (M1), month 3 (M3), and every three months thereafter, when available.ResultsA total of 15 patients were enrolled between August 2022 and October 2024. Three PLWHIV reported moderate pain at the injection site, with one discontinuing treatment at M12. All CAB and RPV plasma concentrations measured after deltoid CAR-LA were comparable with those obtained following gluteal CAR-LA phase 3 studies.ConclusionDeltoïd CAR-LA seems to be a reliable and well-tolerated alternative for PLWHIV with contraindications for gluteal injections."

Journal • Human Immunodeficiency Virus • Infectious Disease • Pain

Feasibility, Fidelity, and Effectiveness of Administering Long-Acting Cabotegravir + Rilpivirine in Infusion Centers in the United States: Findings From the Phase 4 GLACIER Implementation Study. (PubMed, J Int Assoc Provid AIDS Care) - P4 | "BackgroundGLACIER (Giving Long-Acting Cabotegravir plus rilpivirine [CAB + RPV LA] in an Infusion Center [IC]) is a Phase 4 implementation study evaluating the perspective of people living with HIV-1 (participants) and IC staff on CAB + RPV LA delivery at ICs over 8 months.MethodsParticipants and IC staff completed quantitative questionnaires on feasibility (Feasibility of Intervention Measure [FIM]) and acceptability (Acceptability of Intervention Measure [AIM]) at Month (M) 1, M3, and M8; both scales comprised four items, rated on a 1 to 5 Likert scale (1 "completely disagree" to 5 "completely agree"). Qualitative data supported these observations. Of 194 injections, 96.4% were within the treatment window; virological suppression was maintained with no confirmed virological failures or adverse event-related discontinuations.ConclusionsCAB + RPV LA administration at ICs was feasible, acceptable, well-tolerated, and effective.ClinicalTrials.gov..."

Journal • P4 data • Human Immunodeficiency Virus • Infectious Disease

Acute Hepatitis B among PWH Switched to Long-Acting Cabotegravir/Rilpivirine: The Context Matters. (PubMed, Clin Infect Dis) - No abstract available

Journal • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation